ArticleDiagnostics (Basel, Switzerland)2025

Real-World, National Study of Palbociclib in HR+/HER2- Metastatic Breast Cancer: A 2.5-Year Follow-Up PALBO01/2021.

Cristina Marinela Oprean et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.